Compare · DXR vs SYK
DXR vs SYK
Side-by-side comparison of Daxor Corporation (DXR) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXR and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $117.18B, about 2665.0x DXR ($44.0M).
- Over the past year, DXR is up 15.5% and SYK is down 20.0% - DXR leads by 35.6 points.
- SYK has been more active in the news (8 items in the past 4 weeks vs 4 for DXR).
- SYK has more recent analyst coverage (25 ratings vs 0 for DXR).
- Company
- Daxor Corporation
- Stryker Corporation
- Price
- $9.78-9.07%
- $305.64+1.48%
- Market cap
- $44.0M
- $117.18B
- 1M return
- -5.28%
- +4.59%
- 1Y return
- +15.54%
- -20.02%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 4
- 8
- Recent ratings
- 0
- 25
Daxor Corporation
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest DXR
- SEC Form DEF 14A filed by Daxor Corporation
- Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
- SEC Form NT NPORT-P filed by Daxor Corporation
- Amendment: SEC Form 40-8F-2/A filed by Daxor Corporation
- SEC Form 40-17F2 filed by Daxor Corporation
- Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis
- SEC Form 4 filed by Feldschuh Michael Richard
- Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
- Amendment: SEC Form N-CEN/A filed by Daxor Corporation
- SEC Form 4 filed by Michel Robert J
Latest SYK
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation